Brooklyn ImmunoTherapeutics Inc (NYSE:BTX - Get Free Report)'s share price was down 1.5% during trading on Thursday . The stock traded as low as $7.30 and last traded at $7.35. Approximately 385,814 shares were traded during trading, a decline of 46% from the average daily volume of 710,401 shares. The stock had previously closed at $7.46.
Analyst Upgrades and Downgrades
Separately, Wall Street Zen started coverage on Brooklyn ImmunoTherapeutics in a research report on Saturday, May 17th. They set a "hold" rating on the stock.
View Our Latest Stock Report on BTX
Brooklyn ImmunoTherapeutics Price Performance
The company has a market capitalization of $432.37 million, a PE ratio of -3.24 and a beta of 4.61. The firm has a 50-day moving average of $7.28 and a 200 day moving average of $6.07.
About Brooklyn ImmunoTherapeutics
(
Get Free Report)
Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Brooklyn ImmunoTherapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Brooklyn ImmunoTherapeutics wasn't on the list.
While Brooklyn ImmunoTherapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.